The role of the cytochrome P450 1A2 (CYP1A2) rs2472299, rs2470890 and rs11072508 polymorphisms in prostate cancer risk, disease progression and tumour development remains unclear. The potential associations of these three CYP1A2 polymorphisms and haplotypes with prostate cancer susceptibility and its clinicopathological characteristics were therefore investigated. The present case-control study consisted of 522 patients with prostate cancer and 554 healthy controls. High-resolution melting analysis was used to determine the CYP1A2 polymorphisms. No significant association in prostate cancer risk was seen for CYP1A2 rs2472299 and rs11072508. However, a significantly decreased risk of prostate cancer was found for CYP1A2 rs2470890 [odds ratio (OR), 0.67; P=0.02] in the recessive model. After analysis of the associations of clinical status and these three CYP1A2 polymorphisms, the CYP1A2 rs2470890 and rs11072508 polymorphisms showed a positive association with a higher Gleason score (rs2470890 OR, 1.36, P=0.04 in the allelic model; rs11072508 OR, 1.37, P=0.04 in the allelic model and OR, 1.60, P=0.03 in the dominant model). All three polymorphisms showed a significant positive association with pathological T stage in the additive, allelic and dominant genetic models (P<0.05). Haplotype analysis revealed that the most common haplotypes ‘GTT’ and ‘ACC’ were significantly associated with pathological T stages 3 and 4 (OR, 0.62; P=0.02 and OR, 1.54; P=0.03, respectively). A significant association was found between the ‘GTT’ haplotype and the Gleason score (OR, 0.71; P=0.03). In conclusion, these CYP1A2 polymorphisms and haplotypes have the potential to predict prostate cancer disease progression.
CYP1A2polymorphismhaplotypeprostate cancerSlovak populationAgency of Ministry of Education, Science, Research and Sport of the Slovak Republic1/0014/22APVV-15-0181This work was supported by the Agency of Ministry of Education, Science, Research and Sport of the Slovak Republic (grant nos. 1/0014/22 and APVV-15-0181).Introduction
Prostate cancer is a multifactorial disease and the most frequently diagnosed malignancy associated with significant mortality and morbidity in men. The well-established risk factors are age, ethnicity, family history of prostate cancer and genetic predisposition (1). In addition, dietary factors, such as the intake of red meat, and smoking have been considered as potential prostate cancer risk factors (2).
Members of the general population are exposed to a vast number of xenobiotics during the course of their lifetimes, including drugs, industrial chemicals and food procarcinogens (3). The key mechanism for maintaining homeostasis during exposure to various xenobiotics is biotransformation. This process is divided into two phases: Phase I involves oxidation, which introduces a reactive group into the xenobiotics that enter the body or into endogenous compounds; and phase II, which generates water-soluble compounds by the conjugation of the products of phase I reactions or parent compounds with suitable functional groups yielding an excretable product. Biotransformation occasionally results in toxic metabolites (via bioactivation) (4,5).
Among the enzymes that metabolize xenobiotics, the cytochrome P450 (CYP450) enzyme superfamily is the most important and extensively studied group of activation (phase I) enzymes (6). The CYP450 superfamily consists of 57 genes and is divided into 18 families in humans. Only CYP450 families 1, 2 and 3 are responsible for the metabolism of the majority of drugs and other xenobiotics. Moreover, the CYP1 family includes three proteins: CYP1A1, CYP1A2 and CYP1B1 (7). CYP1A2 is expressed mainly in the liver (13–15% of all CYP450), although its expression has also been detected in prostate tissue (8,9). CYP1A2 metabolizes a number of clinical drugs (e.g., analgesics and antipyretics, antipsychotics, antidepressants, anti-inflammatory drugs, the muscle relaxant tizanidine and the lipoxygenase inhibitor zileuton) (10), a number of procarcinogens [e.g., aromatic and heterocyclic amines, polycyclic aromatic hydrocarbons (PAH) and aflatoxin B1] (11,12) and several important endogenous compounds (e.g., oestrogens, melatonin, retinoic acid, arachidonic acid and prostaglandins, bilirubin and uroporphyrinogen) (13–15).
Both environmental and genetic factors affect the activity of CYP1A2. The well-established inducers of CYP1A2 activity are cigarette smoking, habitual heavy coffee consumption, cruciferous vegetables, heavy exercise and grilled meat (16,17). Heterocyclic amines (HCA), derived from meats cooked at high temperature require metabolic activation for the formation of stable HCA-DNA adducts (2). Other mutagens present in cooked meat and formed by the pyrolysis of fat include PAH, e.g., benzo[a]pyrene (B[a]P), which has been shown to be metabolically activated in prostatic tissues (8). The inhibition of B[a]P adduct formation by α-naphthoflavone, an inhibitor of the CYP1 family (18), indicates that CYP1 enzymes are at least partially responsible for the metabolic activation of PAH in human prostatic tissue (8). Similarly, constituents of cigarette smoke, such as PAH, require metabolic activation, evasion of detoxification processes and subsequent binding to DNA to exert their carcinogenic action (19). Some drugs such as phenobarbital, carbamazepine, omeprazole and rifampicin, are important inducers of CYP1A2 (20), whereas other drugs such as fluvoxamine, quinolone antibiotics and oral contraceptives act as CYP1A2 inhibitors (21,22).
Interindividual, sex-related and ethnic differences in CYP1A2 activity have been reported and may cause variation in the activation of some carcinogens and, thereby, in cancer susceptibility (23). Notably, 35–75% of the interindividual variability in CYP1A2 activity has been suggested to be attributable to genetic factors (17).
To date, >177 single nucleotide polymorphisms (SNPs) in the upstream sequence and more than 21 variant alleles (*1B to *21) of human CYP1A2 have been identified (https://www.pharmvar.org/htdocs/archive/cyp1a2.htm), although the functional consequences of most of these are unknown (23). Due to the role of CYP1A2 in tumorigenesis, numerous investigations have been undertaken to determine the effects of CYP1A2 polymorphisms on various diseases, including cancer, and several meta-analyses have been published with conflicting results (24,25). Moreover, to the best of our knowledge, the possible association of CYP1A2 rs2472299, rs2470890 and rs11072508 polymorphisms, and prostate cancer risk and progression has not yet been studied. The effect of these polymorphisms and haplotypes on prostate cancer susceptibility and the clinicopathological features of the disease was therefore investigated in the present study.
Materials and methodsStudy population
The present case-control study was approved by the Ethical Board of Jessenius Faculty of Medicine, Comenius University (Martin, Slovak Republic) and conducted in accordance with The Declaration of Helsinki. Most of the subjects were also enrolled in our previous studies (26,27).
The inclusion and exclusion criteria for the case group were as follows: i) age ≥50 years; ii) Caucasian; and iii) histologically confirmed prostate cancer. The indication for prostate biopsy was either a suspicious finding on digital rectal examination (DRE) or elevated serum levels of prostate specific antigen (PSA), or both. Patients with prior or present evidence of other cancers or other major pathologies and patients who had a first-degree relative (brother or father) with a confirmed diagnosis of prostate cancer were excluded.
The inclusion criteria for the control group were as follows: i) age ≥50 years; ii) Caucasian; iii) no current or previous diagnoses of cancer; iv) no evidence of family history of prostate cancer; and v) negative DRE and negative serum PSA according to age-specific reference values (28).
A one-to-one case-control study was designed with an estimated total number of 408 patients and controls each. This number provided an 80% power to detect a difference in the proportions of at least 0.1 in any direction at a significance level of 0.05 assuming the most conservative prevalence in controls (0.5). To account for the non-probabilistic nature of the data-generating process and potential drop-out, the sample size was increased by 35% (408 to 551). A total of 1,076 Caucasian men were studied, including 522 patients with prostate cancer and 554 healthy controls, at the Department of Urology, Jessenius Faculty of Medicine and University Hospital Martin, Comenius University in Bratislava. Prostate cancer patients and controls were enrolled from May 2005 to December 2019. All subjects agreed to participate in the study and written informed consent was obtained from all. Venous blood (3 ml) from all participants was withdrawn into Vacutainer tubes containing EDTA as the anticoagulant.
For all of the patients with prostate cancer, histological evaluation was performed on specimens collected using prostate needle biopsy or transurethral resection of the prostate. Biopsy materials were immediately fixed in a 10% solution of buffered formaldehyde for 24 h at 25°C. Fixed material was embedded into paraffin blocks and histological slides of 3–4 µm thickness were cut and stained using a commercial Hematoxylin and Eosin Staining Kit (cat. no. ab245880; Abcam) according to the manufacturer's protocols. The protocol of the International Society of Urological Pathology was used for histological slides analysis and the final biopsy record (29). Histological slides were assessed using a BX45 light microscope (Olympus Corporation). The Gleason score for the histopathological grade (30) was recorded and the patients were divided into two groups as follows: i) low-grade, score ≤7; and ii) high-grade, score >7.
Cases and controls were tested for total serum prostatic specific antigen (PSA) levels using a Beckman Coulter Access® Hybritech® assay (cat. no. 37200, Beckman Coulter, Inc.) according to the manufacturer's protocol.
Genotyping
Genomic DNA was isolated from peripheral blood samples (300 µl) using a Wizard® Genomic DNA Purification Kit (catalogue no. A1125; Promega Corporation) and ethanol precipitation according to the manufacturer's protocol.
Three tagged SNPs, capturing common variability of the CYP1A2 gene, were adopted according to the approach described by Matakova et al (31). The common variability given by the presence of polymorphic sites with minor allele frequency >10% was studied. Briefly, an algorithm implemented in Haploview 4.2 (32) was used with the 1000 Genomes Project data (for population of Caucasian residents with northern and western European ancestry from UT, USA, CEU from phase 1 release; http://www.internationalgenome.org/home) from an extended genomic region of the CYP1A2 gene (33). Three SNPs resulted from the analysis: rs2472299 from the 5′UTR of the CYP1A2 gene (NC_000015.10:g.74741059A>G), the synonymous variant rs2470890 (NC_000015.10:g.74755085T>C), and rs11072508 from the 3′UTR of the CYP1A2 gene (NC_000015.10:g.74770056C>T).
For the genotyping of selected SNPs, high-resolution melting analysis (HRMA) was carried out on a LightCycler 480 II (Roche Diagnostics). HRMAs were performed with the LightCycler® 480 High Resolution Melting Master Kit (cat. no. 0490963100; Roche Diagnostics GmbH) according to the manufacturer's protocols. Primer3Plus software (34) was used for the selection of primer sequences when designing genotyping reactions. Positive and negative controls were included in all reactions. The positive controls were external DNA samples with all three of the genotypes identified in pilot runs as having their own distinct melting curve. The negative control was a ‘no template’ control with nuclease-free water as a ‘template’ without a melting curve at the end of the run analysis. The specific primers and the PCR conditions are shown in Table I.
Statistical analysis
Genetic analysis of the determined genotypes and association analysis between each SNP and the defined groups of study participants were performed using PLINK 1.07 software (35). Five genetic models (allelic, dominant, recessive, genotypic and additive) were constructed to evaluate the association between CYP1A2 rs2472299, rs2470890 and rs11072508 polymorphisms and prostate cancer risk. If D was the minor allele and d was the major allele then the models were constructed as follows: allelic, D vs. d; dominant, DD, Dd vs. dd; recessive, DD vs. Dd,dd; genotypic, DD vs. Dd vs. dd; and additive, DD vs. Dd and Dd vs. dd.
All genetic model associations were analysed using Fisher's exact test, with the exception of the additive model, which was analysed using the Cochran-Armitage trend test as this works with zero, one and two weights for each individual genotype, according to the burden of the minor allele which was required as the additive model assumed that the effect of a heterozygous genotype was halfway between the other two homogroups. The association of haplotypes was analysed using Pearson's χ2-test. P<0.05 was considered to indicate a statistically significant difference.
PLINK calculated haplotypes based on multi-marker predictors using the standard E-M algorithm. Haplotype frequencies were estimated based on the distribution of a probabilistically-inferred set of haplotypes for each individual. To perform haplotype association tests, PLINK used Pearson's χ2-test. P<0.05 was considered to indicate a statistically significant difference.
Results
The 522 patients with prostate cancer had a mean ± SD age of 65.8±9.5 years and a serum PSA concentration of 44.3±4.5 ng/ml. Out of 421 patients, 275 (65.3%) had a Gleason score ≤7 and 146 (34.7%) had a Gleason score >7. In the remaining 101 cases, the final pathological grade was not included in the analysis since the grading had been performed using other grading systems. A total of 119 patients (50%) had tumour stages pT1/pT2 and an equal number had tumour stages pT3/pT4. In 284 of the 522 patients the pathological stage was not included as the patients didn't undergo surgical removal of the prostate in the University Hospital Martin. The 554 healthy controls had a mean ± SD age of 64.7±10.3 years and a serum PSA concentration of 3.2±0.5 ng/ml.
The genotypic distribution for all SNPs in the controls and patients with prostate cancer was consistent with the Hardy-Weinberg equilibrium (P<0.05, data not shown). For further analyses of the genotype frequencies of all SNPs, five genetic models (genotypic, additive, allelic, dominant and recessive) were used, as shown in Table II. No significant association with susceptibility for prostate cancer for the CYP1A2 rs2472299 and rs11072508 polymorphisms was found in any of the genetic models. The genotype frequencies differed significantly between prostate cancer and control groups in terms of the CYP1A2 rs2470890 polymorphism (P=0.03) in the genotypic model. For rs2470890, a significantly decreased risk of prostate cancer was observed in the recessive model [CC vs. CT + TT; odds ratio (OR), 0.67; 95% confidence interval (CI), 0.48-0.93; P=0.02].
The patients were further divided by PSA levels (<10 and ≥10 ng/ml), Gleason score (≤7 and >7) and pathological T stage (pT1/pT2 and pT3/pT4). As shown in Table III, stratification analysis of the CYP1A2 rs2472299 and rs2470890 polymorphisms revealed no significant association with PSA levels in any of the genetic models. However, a significant association was observed between the CYP1A2 rs11072508 polymorphism and serum PSA levels ≥10 ng/ml (OR, 1.51; 95% CI, 1.01-2.26; P=0.05) in the dominant model. The additive genetic model showed a significant association between the CYP1A2 rs2470890 and rs11072508 polymorphisms with the development of higher grade carcinomas (Gleason score >7; P=0.03 and P=0.03, respectively). Moreover, the CYP1A2 rs2470890 polymorphism was significantly associated with the development of higher grade carcinomas (Gleason score >7) in the allelic genetic model (OR, 1.36; 95% CI, 1.02-1.82; P=0.04). Furthermore, a significant association was observed between the rs11072508 polymorphism and higher grade carcinomas (Gleason score >7) in the allelic (OR, 1.37; 95% CI, 1.03-1.83; P=0.04) and dominant (OR, 1.60; 95% CI, 1.04-2.45; P=0.03) genetic models. No significant associations were found in any of the genetic models for the rs2472299 polymorphism (P>0.05) with a high Gleason score risk. The associations between CYP1A2 polymorphisms and pathological T stage were also determined (Table III). CYP1A2 rs2472299, rs2470890 and rs11072508 showed a significant association with pathological T stage in additive (P=0.02, P=0.007 and P=0.03, respectively), allelic (OR, 1.59, P=0.02; OR, 1.67, P=0.009; and OR, 1.49, P=0.05, respectively) and dominant (OR, 1.79, P=0.03; OR, 2.31, P=0.004; and OR, 1.94, P=0.03, respectively) genetic models.
The linkage disequilibrium, measured using the squared correlation coefficient r2, between each SNP was in the range 0.683-0.829. Analysis of the CYP1A2 gene revealed five haplotype groups among which the ‘GTT’ and ‘ACC’ haplotypes (order of SNPs in haplotype: rs2472299>rs2470890>rs11072508) were the most common in controls (91.8%) and patients with prostate cancer (92.9%) (Table IV). Haplotype analysis revealed that haplotypes did not alter the prostate cancer risk. The association between the haplotypes of the CYP1A2 gene and the clinical outcomes were also analysed (Table V). A significant association was found between the ‘GTT’ haplotype and the Gleason score and the pathological T stage (OR, 0.71, P=0.03; and OR, 0.62, P=0.02, respectively), suggesting the protective effect of the major ‘GTT’ haplotype in prostate cancer pathology. Moreover, the ‘ACC’ haplotype was associated with pT3/pT4 (OR, 1.54; 95% CI 1.04-2.26; P=0.03). No associations were detected between the haplotypes and serum PSA values (P>0.05).
Discussion
To the best of our knowledge, the present study is the first to analyse the association of CYP1A2 polymorphisms rs2472299, rs2470890 and rs11072508, and haplotypes with the risk and clinicopathological features of prostate cancer in the Slovak population. The lack of significant associations in the present study among the CYP1A2 rs2472299 and rs11072508 polymorphisms and prostate cancer risk suggests that the direct impact of these polymorphisms on prostate cancer susceptibility is limited. In the case of polymorphism CYP1A2 rs2470890, an association with significantly reduced prostate cancer risk for CC genotype carriers in the recessive model was observed.
The associations of genetic variations of CYP1A2 with clinicopathological characteristics (serum PSA, Gleason score, pathological T stage) were further examined in order to evaluate potential associations with the aggressive form of prostate cancer. Notably, all three studied CYP1A2 polymorphisms were significantly associated with pathological T stage (pT3/pT4) in the additive, allelic and dominant genetic models. Moreover, rs11072508 and rs2470890 polymorphic variants were found to have significant associations with higher grade carcinomas (Gleason score >7) in the additive, allelic and dominant genetic models. However, no significant association was found between these CYP1A2 polymorphisms and serum PSA levels in patients with prostate cancer.
In case-control studies, statistical power to detect disease susceptibility depends, among other factors, on the selected genetic models. Therefore, it is important to carefully choose the most accurate and representative genotype model (36,37). However, a commonly accepted strategy to select the best model has not been developed (38). Thus, dominant, recessive, and additive models are often used. The dominant model assumes that having one or more copies of a major allele increases the risk of having an altered phenotype in comparison with minor allele. The recessive model assumes that one or more copies of minor allele has the strongest impact on phenotype and, thus, requires a major allele homozygote genotype to alter risk. The additive model ranks genotypes with two allele copies over those that have one or none from highest to lowest impact on risk (37,38).
Only one study has investigated the association of these three CYP1A2 polymorphisms and haplotypes with cancer risk. Matakova et al (31) studied the risk of lung cancer in a case-control study of 105 patients with lung cancer and 189 controls. The study reported a significant association of the CYP1A2 rs2470890 and rs2422299 polymorphisms with lung cancer risk. Moreover, it was shown that the haplotype ‘ACC’, which is present at the highest frequency, was associated with an increased lung cancer risk and that the rare haplotype ‘GTC’ was significantly associated with a decreased lung cancer risk in the Slovak population. These polymorphisms have been studied alone or in combination with other polymorphisms in various types of cancer, including lung cancer (39,40), hepatocellular carcinoma (41), breast cancer (42,43), and colorectal cancer (44), in various population groups.
A number of research groups have investigated the relationship between other CYP1A2 polymorphisms (rs762551, rs2069514, rs2069525 and rs5762551) and prostate cancer risk. However, the results were inconsistent (42–48). Some of these studies have examined the interaction between the CYP1A2 polymorphisms and environmental exposure, such as cigarette smoking or the high intake of grilled-smoked meat. For example, Koda et al (45) reported that CYP1A2 rs762551 risk genotypes (AA, CA, and CA + AA) were associated with an increased risk of prostate cancer among Japanese individuals with a high heterocyclic aromatic amine intake. It was speculated that the higher activation of heterocyclic aromatic amines in the liver and/or prostate by CYP1A2 is important for the increased risk of prostate cancer. Furthermore, another study revealed an association between smoking status, the CYP1A2 rs762551 polymorphism and localized prostate cancer risk among white non-Hispanic individuals (49).
A possible explanation for the inconsistent results between these studies might be that the same polymorphisms serve different roles in cancer susceptibility in different ethnicities and in different tumour types (40). Moreover, prostate cancer is a heterogeneous disease and CYP1A2 polymorphisms alone might not predispose individuals to prostate cancer. Therefore, gene-gene interactions among several different genes should be investigated in order to explain the pathogenesis of prostate cancer. Factors other than genetic ones, such as lifestyle (smoking, drinking and dietary habits) and environmental exposure, might influence CYP1A2 enzyme activity. High in vivo CYP1A2 activity has been suggested to be a susceptibility factor for bladder, colon and rectum cancer in which exposure to aromatic and heterocyclic amines has been implicated in the aetiology of the disease (50). Additionally, the CYP1A2 rs2069514 and rs762551 polymorphisms are reported to be associated with increased enzyme activity in smokers (51,52).
Hormones, such as androgens and oestrogens, are known to be contributors to the development and progression of prostate cancer (1,53). Furthermore, the CYP1A2 enzyme is well documented as being the most active in the metabolic conversion of oestradiol to 2-hydroxyoestradiol (54). The increased formation of 2-hydroxylated oestrogens has been shown to contribute to a decreased susceptibility to breast cancer, since 2-hydroxyoestrogens can weakly bind only to the oestrogen receptor (55). Therefore, we hypothesize that the altered CYP1A2 enzyme activity in oestrogen metabolism partially affects prostate cancer development.
In conclusion, the present study demonstrated a significantly decreased risk of prostate cancer only with the CYP1A2 rs2470890 polymorphism in the recessive genetic model in the Slovak population. The CYP1A2 rs2472299 and rs11072508 polymorphisms were not shown to be significantly associated with prostate cancer risk in this population. Moreover, the association of the CYP1A2 rs2470890 and rs11072508 polymorphisms was observed with the development of higher grade carcinomas (Gleason score >7) in the allelic (rs2470890 and rs11072508) and dominant (rs11072508) genetic models. Furthermore, all three polymorphisms were found to have a statistically significant association with pathological T stage in the additive, allelic and dominant genetic models. The haplotype analysis indicated the protective effect of the most frequent haplotype ‘GTT’ was associated with high-grade carcinomas (Gleason score >7) and pT3/pT4 in patients with prostate cancer. The significant association of the second most common haplotype, ‘ACC’, with higher pathological T stage (pT3/pT4) was observed. Further research is required to confirm the associations between these CYP1A2 polymorphisms and oncological outcome, and to interpret their biological significance in disease phenotype. Additional genetic and functional studies are also needed to validate the findings of the present study and to clarify the role of the ‘GTT’ and ‘ACC’ haplotypes in CYP1A2 enzyme activity.
Acknowledgements
Not applicable.
Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.
Authors' contributions
MSK and MŠ confirm the authenticity of all the raw data. MKS, MV, JK and DE made substantial contributions to conception and design of the present study. MŠ, DD and JJ performed acquisition of data. PK, MH, MKB and RD performed analysis and interpretation of the data. All authors read and approved the final manuscript.
Ethics approval and consent to participate
This case-control study was approved by the Ethical Board of Jessenius Faculty of Medicine, Comenius University (Martin, Slovak Republic; approval no. EK 6/2022) and conducted in accordance with The Declaration of Helsinki. Written informed consent was obtained from all subjects.
Patient consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
AbbreviationsCYP1A2
cytochrome P450 1A2
HRMA
high-resolution melting analysis
PAH
polycyclic aromatic hydrocarbons
HCA
heterocyclic amines
B[a]P
benzo[a]pyrene
SNPs
single nucleotide polymorphisms
CI
confidence interval
OR
odds ratio
PSA
prostatic specific antigen
ReferencesZiaranSVarchulova NovakovaZBohmerDDanisovicLBiomarkers for determination prostate cancer: Implication for diagnosis and prognosisNeoplasma62683691201510.4149/neo_2015_08226278153JoshiADCorralRCatsburgCLewingerJPKooJJohnEMInglesSASternMCRed meat and poultry, cooking practices, genetic susceptibility and risk of prostate cancer: Results from a multiethnic case-control studyCarcinogenesis3321082118201210.1093/carcin/bgs24222822096LiskaDJThe detoxification enzyme systemsAltern Med Rev318719819989630736AlmazrooOAMiahMKVenkataramananRDrug metabolism in the liverClin Liver Dis21120201710.1016/j.cld.2016.08.00127842765KaurGGuptaSKSinghPAliVKumarVVermaMDrug-metabolizing enzymes: Role in drug resistance in cancerClin Transl Oncol2216671680202010.1007/s12094-020-02325-732170639AnzenbacherPAnzenbacherováECytochromes P450 and metabolism of xenobioticsCell Mol Life Sci58737747200110.1007/PL0000089711437235GoREHwangKAChoiKCCytochrome P450 1 family and cancersJ Steroid Biochem Mol Biol1472430201510.1016/j.jsbmb.2014.11.00325448748WilliamsJAMartinFLMuirGHHewerAGroverPLPhillipsDHMetabolic activation of carcinogens and expression of various cytochromes P450 in human prostate tissueCarcinogenesis2116831689200010.1093/carcin/21.9.168310964100ZhouSFWangBYangLPLiuJPStructure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2Drug Metab Rev42268354201010.3109/0360253090328647619961320ZangerUMSchwabMCytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variationPharmacol Ther138103141201310.1016/j.pharmthera.2012.12.00723333322EatonDLGallagherEPBammlerTKKunzeKLRole of cytochrome P4501A2 in chemical carcinogenesis: Implications for human variability in expression and enzyme activityPharmacogenetics5259274199510.1097/00008571-199510000-000018563766GunesADahlMLVariation in CYP1A2 activity and its clinical implications: Influence of environmental factors and genetic polymorphismsPharmacogenomics9625637200810.2217/14622416.9.5.62518466106NebertDWDaltonTPThe role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesisNat Rev Cancer6947960200610.1038/nrc201517128211ZaccaroCSweitzerSPipinoSGormanNSinclairPRSinclairJFNebertDWDe MatteisFRole of cytochrome P450 1A2 in bilirubin degradation studies in Cyp1a2 (−/-) mutant miceBiochem Pharmacol61843849200110.1016/S0006-2952(01)00568-811274970LambrechtRWJacobsJMSinclairPRSinclairJFInhibition of uroporphyrinogen decarboxylase activity. The role of cytochrome P-450-mediated uroporphyrinogen oxidationBiochem J269437441199010.1042/bj26904372117439DjordjevicNGhotbiRBertilssonLJankovicSAklilluEInduction of CYP1A2 by heavy coffee consumption in Serbs and SwedesEur J Clin Pharmacol64381385200810.1007/s00228-007-0438-618157525RasmussenBBBrixTHKyvikKOBrøsenKThe interindividual differences in the 3-demthylation of caffeine alias CYP1A2 is determined by both genetic and environmental factorsPharmacogenetics12473478200210.1097/00008571-200208000-0000812172216ShimadaTEl-BayoumyKUpadhyayaPSutterTRGuengerichFPYamazakiHInhibition of human cytochrome P450-catalyzed oxidations of xenobiotics and procarcinogens by synthetic organoselenium compoundsCancer Res574757476419979354437RodgmanASmithCJPerfettiTAThe composition of cigarette smoke: A retrospective, with emphasis on polycyclic componentsHum Exp Toxicol19573595200010.1191/09603270070154651411211997HladunOPapaseitEMartínSBarriocanalAMPoyatosLFarréMPérez-MañáCInteraction of energy drinks with prescription medication and drugs of abusePharmaceutics131532202110.3390/pharmaceutics1310153234683828ChristensenMTybringGMiharaKYasui-FurokoriNCarrilloJARamosSIAnderssonKDahlMLBertilssonLLow daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19)Clin Pharmacol Ther71141152200210.1067/mcp.2002.12178811907488FaberMSJetterAFuhrUAssessment of CYP1A2 activity in clinical practice: Why, how, and when?Basic Clin Pharmacol Toxicol97125134200510.1111/j.1742-7843.2005.pto_973160.x16128905ZhouSFYangLPZhouZWLiuYHChanEInsights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1A2AAPS J11481494200910.1208/s12248-009-9127-y19590965DalyAKPolymorphic variants of cytochrome P450: Relevance to cancer and other diseasesAdv Pharmacol7485111201510.1016/bs.apha.2015.03.00126233904VukovicVIanualeCLeonciniEPastorinoRGualanoMRAmoreRBocciaSLack of association between polymorphisms in the CYP1A2 gene and risk of cancer: Evidence from meta-analysesBMC Cancer1683201610.1186/s12885-016-2096-526865042HívešMJurečekováJKlimentJGrendárMKaplánPDušenkaREvinDVilčkováMHolečkováKHSivoňováMKRole of genetic variations in CDK2, CCNE1 and p27KIP1 in prostate cancerCancer Genomics Proteomics19362371202210.21873/cgp.2032635430569SivonovaMKJurecekovaJKaplanPHivesMGrendarMTomascovaADusenkaRDrobkovaHEvinDKlimentJAssociation of MDM2 T309G (rs2279744) polymorphism and expression changes with risk of prostate cancer in the Slovak populationAnticancer Res4062576264202010.21873/anticanres.1464633109563PientaKJCritical appraisal of prostate-specific antigen in prostate cancer screening: 20 Years laterUrology73(5 Suppl)S11S20200910.1016/j.urology.2009.02.01619375622van LeendersGJLHvan der KwastTHGrignonDJEvansAJKristiansenGKweldamCFLitjensGMcKenneyJKMelamedJMottetNThe 2019 international society of urological pathology (ISUP) consensus conference on grading of prostatic carcinomaAm J Surg Pathol44e87e99202010.1097/PAS.000000000000149732459716EpsteinJIEgevadLAminMBDelahuntBSrigleyJRHumphreyPAGrading CommitteeThe 2014 international society of urological pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma: Definition of grading patterns and proposal for a new grading systemAm J Surg Pathol40244252201610.1097/PAS.000000000000053026492179MatakovaTHalasovaEDzianAHrubyRHalasaMJavorkaKSkerenovaMAssociations of CYP1A2 polymorphisms with the risk haplotypes in lung cancer in the Slovak populationAdv Exp Med Biol9112332201610.1007/5584_2016_22026987327BarrettJCFryBMallerJDalyMJHaploview: Analysis and visualization of LD and haplotype mapsBioinformatics21263265200510.1093/bioinformatics/bth457152973001000 Genomes Project ConsortiumAutonABrooksLDDurbinRMGarrisonEPKangHMKorbelJOMarchiniJLMcCarthySMcVeanGAAbecasisGRA global reference for human genetic variationNature5266874201510.1038/nature1539326432245UntergasserANijveenHRaoXBisselingTGeurtsRLeunissenJAMPrimer3Plus, an enhanced web interface to Primer3Nucleic Acids Res35(Web Server Issue)W71W74200710.1093/nar/gkm30617485472PurcellSNealeBTodd-BrownKThomasLFerreiraMABenderDMallerJSklarPde BakkerPIDalyMJShamPCPLINK: A tool set for whole-genome association and population-based linkage analysesAm J Hum Genet81559575200710.1086/51979517701901LewisCMGenetic association studies: Design, analysis and interpretationBrief Bioinform3146153200210.1093/bib/3.2.14612139434HoritaNKanekoTGenetic model selection for a case-control study and a meta-analysisMeta Gene518201510.1016/j.mgene.2015.04.00326042205ClarkeGMAndersonCAPetterssonFHCardonLRMorrisAPZondervanKTBasic statistical analysis in genetic case-control studiesNat Protoc6121133201110.1038/nprot.2010.18221293453AldrichMCSelvinSHansenHMBarcellosLFWrenschMRSisonJDKelseyKTBufflerPAQuesenberryCPJrSeldinMFWienckeJKCYP1A1/2 haplotypes and lung cancer and assessment of confounding by population stratificationCancer Res6923402348200910.1158/0008-5472.CAN-08-257619276377RotunnoMYuKLubinJHConsonniDPesatoriACGoldsteinAMGoldinLRWacholderSWelchRBurdetteLPhase I metabolic genes and risk of lung cancer: Multiple polymorphisms and mRNA expressionPLoS One4e5652200910.1371/journal.pone.000565219479063ChenXWangHXieWLiangRWeiZZhiLZhangXHaoBZhongSZhouGAssociation of CYP1A2 genetic polymorphisms with hepatocellular carcinoma susceptibility: A case-control study in a high-risk region of ChinaPharmacogenet Genomics16219227200610.1097/01.fpc.0000194424.20393.c616495781BaiXXieJSunSZhangXJiangYPangDThe associations of genetic polymorphisms in CYP1A2 and CYP3A4 with clinical outcomes of breast cancer patients in northern ChinaOncotarget83836738377201710.18632/oncotarget.1635928418906AndersonLNCotterchioMMireaLOzcelikHKreigerNPassive cigarette smoke exposure during various periods of life, genetic variants, and breast cancer risk among never smokersAm J Epidemiol175289301201210.1093/aje/kwr32422247046WangHYamamotoJFCabertoCSaltzmanBDeckerRVogtTMYokochiLChanockSWilkensLRLe MarchandLGenetic variation in the bioactivation pathway for polycyclic hydrocarbons and heterocyclic amines in relation to risk of colorectal neoplasiaCarcinogenesis32203209201110.1093/carcin/bgq23721081473KodaMIwasakiMYamanoYLuXKatohTAssociation between NAT2, CYP1A1, and CYP1A2 genotypes, heterocyclic aromatic amines, and prostate cancer risk: A case control study in JapanEnviron Health Prev Med2272201710.1186/s12199-017-0681-029165164WeiWGeJPDongJGaoJPZhangZYGongJSingle nucleotide polymorphisms of CYP1A2 and their correlation with prostate cancerZhonghua Nan Ke Xue1799810012011(In Chinese)22141270CunninghamJMHebbringSJMcDonnellSKCicekMSChristensenGBWangLJacobsenSJCerhanJRBluteMLSchaidDJThibodeauSNEvaluation of genetic variations in the androgen and estrogen metabolic pathways as risk factors for sporadic and familial prostate cancerCancer Epidemiol Biomarkers Prev16969978200710.1158/1055-9965.EPI-06-076717507624MurataMWatanabeMYamanakaMKubotaYItoHNagaoMKatohTKamatakiTKawamuraJYataniRShiraishiTGenetic polymorphisms in cytochrome P450 (CYP) 1A1, CYP1A2, CYP2E1, glutathione S-transferase (GST) M1 and GSTT1 and susceptibility to prostate cancer in the Japanese populationCancer Lett165171177200110.1016/S0304-3835(01)00398-611275366ShahabiACorralRCatsburgCJoshiADKimALewingerJPKooJJohnEMInglesSASternMCTobacco smoking, polymorphisms in carcinogen metabolism enzyme genes, and risk of localized and advanced prostate cancer: Results from the California collaborative prostate cancer studyCancer Med316441655201410.1002/cam4.33425355624GooderhamNJMurraySLynchAMEdwardsRJYadollahi-FarsaniMBrattCRichKJZhaoKMurrayBPBhadresaSHeterocyclic amines: Evaluation of their role in diet associated human cancerBr J Clin Pharmacol429198199610.1046/j.1365-2125.1996.37513.x8807149ZhenzhenLXianghuaLNingSZhanGChuanchuanRJieLCurrent evidence on the relationship between three polymorphisms in the CYP1A2 gene and the risk of cancerEur J Cancer Prev22607619201310.1097/CEJ.0b013e32835f3bd223462460GhotbiRChristensenMRohHKIngelman-SundbergMAklilluEBertilssonLComparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and KoreansEur J Clin Pharmacol63537546200710.1007/s00228-007-0288-217370067WigleDTTurnerMCGomesJParentMERole of hormonal and other factors in human prostate cancerJ Toxicol Environ Health B Crit Rev11242259200810.1080/1093740070187354818368555TsuchiyaYNakajimaMYokoiTCytochrome P450-mediated metabolism of estrogens and its regulation in humanCancer Lett227115124200510.1016/j.canlet.2004.10.00716112414SamavatHKurzerMSEstrogen metabolism and breast cancerCancer Lett356231243201510.1016/j.canlet.2014.04.01824784887
Primer sets and PCR conditions.
CYP1A2 SNP
Primer sequence, 5′-3′
Amplicon, bp
PCR conditions
rs2472299
F: TCACATGTTGAGCTGAGGAGT
60
Initial denaturation 95°C/5 min; 95°C/10 sec, 54°C/10 sec, 72°C/10 sec, 40 cycles, final extension 72°C/4 min.
R: CCCTTATCAATTTCTTCAGGCATTCA
rs2470890
F: CTGTGAACATGTCCAGGCG
65
Initial denaturation 95°C/5 min; 95°C/10 sec, 58°C/10 sec, 72°C/10 sec, 40 cycles; final extension 72°C/4 min.
R: CCTCAGAATGGTGGTGTCTT
rs11072508
F: GGCACTTTGTCCCACTTAGTCC
79
Initial denaturation 95°C/5 min; 95°C/10 sec, 58°C/10 sec, 72°C/10 sec, 40 cycles; final extension 72°C/4 min.
Genotype and allele frequencies of CYP1A2 polymorphisms in patients with prostate cancer and the healthy controls.
CYP1A2
A1
A2
Model
Prostate cancer, n
Healthy controls, n
P-valuea
OR (95% CI)
rs2472299
A
G
GENOe
58/243/221
75/244/235
0.45
NA
A
G
ADDf
359/685
394/714
0.57
NA
A
G
ALLELICb
359/685
394/714
0.58
0.95 (0.79-1.13)
A
G
DOMc
301/221
319/235
1.00
1.00 (0.79-1.28)
A
G
RECd
58/464
75/479
0.23
0.79 (0.55-1.15)
rs2470890
C
T
GENOe
66/267/189
99/248/207
0.03
NA
C
T
ADDf
399/645
446/662
0.33
NA
C
T
ALLELICb
399/645
446/662
0.35
0.92 (0.77-1.09)
C
T
DOMc
333/189
347/207
0.71
1.05 (0.82-1.35)
C
T
RECd
66/456
99/455
0.02
0.67 (0.48-0.93)
rs11072508
C
T
GENOe
66/267/189
88/266/200
0.29
NA
C
T
ADDf
399/645
442/666
0.42
NA
C
T
ALLELICb
399/645
442/666
0.45
0.93 (0.78-1.11)
C
T
DOMc
333/189
354/200
1.00
0.99 (0.78-1.28)
C
T
RECd
66/456
88/466
0.14
0.77 (0.54-1.08)
P-values calculated using Fisher's exact test, except for ADD where Cochran-Armitage trend test was used;
allelic model, D vs. d;
dominant model, DD, Dd vs. dd;
recessive model, DD vs. Dd, dd;
genotypic model, DD vs. Dd vs. dd; and
additive model, DD vs. Dd and Dd vs. dd. A1, minor allele; A2, major allele; GENO, genotypic model; ADD, additive model; ALLELIC, allelic model; DOM, dominant model; REC, recessive model; CYPIA1, cytochrome P450 1A2; OR, odds ratio; CI, confidence interval; NA, not available (design of association test does not generate OR); D, the minor allele; d, the major allele.
Risk of prostate cancer associated with the CYP1A2 polymorphisms and clinicopathological characteristics of patients.
PSA
Gleason score
Pathological T stage
CYP1A2
A1
A2
Model
<10 ng/ml, n
≥10 ng/ml, n
OR (95% CI)
P-valuea
≤7, n
>7, n
OR (95% CI)
P-valuea
pT1/pT2, n
pT3/pT4, n
OR (95% CI)
P-valuea
rs2472299
A
G
GENOe
26/93/90
24/105/85
NA
0.64
28/122/125
19/70/57
NA
0.39
11/48/58
18/53/39
NA
0.07
A
G
ADDf
145/273
153/275
NA
0.74
178/372
108/184
NA
0.17
70/164
89/131
NA
0.02
A
G
ALLELICb
145/273
153/275
1.05 (0.79-1.39)
0.77
178/372
108/184
1.23 (0.91-1.65)
0.19
70/164
89/131
1.59 (1.08-2.35)
0.02
A
G
DOMc
119/90
129/85
1.15 (0.78-1.69)
0.49
150/125
89/57
1.30 (0.87-1.96)
0.22
59/58
71/39
1.79 (1.05-3.05)
0.03
A
G
RECd
26/183
24/190
0.89 (0.49-1.61)
0.76
28/247
19/127
1.32 (0.71-2.46)
0.42
11/106
18/92
1.89 (0.85-4.19)
0.16
rs2470890
C
T
GENOe
26/103/80
31/115/68
NA
0.38
30/135/110
24/77/45
NA
0.09
14/50/53
19/62/29
NA
0.01
C
T
ADDf
155/263
177/251
NA
0.18
195/355
125/167
NA
0.03
78/156
100/120
NA
0.007
C
T
ALLELICb
155/263
177/251
1.19 (0.91-1.57)
0.21
195/355
125/167
1.36 (1.02-1.82)
0.04
78/156
100/120
1.67 (1.14-2.44)
0.009
C
T
DOMc
129/80
146/68
1,33 (0.89-1.99)
0.18
165/110
101/45
1.49 (0.97-2.91)
0.07
64/53
81/29
2.31 (1.32-4.05)
0.004
C
T
RECd
26/183
31/183
1.19 (0.68-2.09)
0.57
30/245
24/122
1.61 (0.90-2.87)
0.13
14/103
19/91
1.54 (0.73-3.24)
0.27
rs11072508
C
T
GENOe
26/100/83
30/119/65
NA
0.13
31/134/110
23/80/43
NA
0.07
15/54/48
19/62/29
NA
0.07
C
T
ADDf
152/266
179/249
NA
0.09
196/354
126/166
NA
0.03
84/150
100/120
NA
0.03
C
T
ALLELICb
152/266
179/249
1.26 (0.95-1.66)
0.11
196/354
126/166
1.37 (1.03-1.83)
0.04
84/150
100/120
1.49 (1.02-2.17)
0.05
C
T
DOMc
126 83
149/65
1.51 (1.01-2.26)
0.05
165/110
103/43
1.60 (1.04-2.45)
0.03
69/48
81/29
1.94 (1.11-3.41)
0.03
C
T
RECd
26/183
30/184
1.15 (0.65-2.02)
0.67
31/244
23/123
1.47 (0.82-2.63)
0.22
15/102
19/91
1.42 (0.68-2.96)
0.36
P-values calculated using Fisher's exact test, except for ADD where Cochran-Armitage trend test was used;
allelic model, D vs. d;
dominant model, DD, Dd vs. dd;
recessive model, DD vs. Dd, dd;
genotypic model, DD vs. Dd vs. dd; and
additive model, DD vs. Dd and Dd vs. dd. A1, minor allele; A2, major allele; GENO, genotypic model; ADD, additive model; ALLELIC, allelic model; DOM, dominant model; REC, recessive model; CI, confidence interval; OR, odds ratio; PSA, prostatic specific antigen; CYPIA1, cytochrome P450 1A2; NA, not available (design of association test does not generate OR); D, the minor allele; d, the major allele.
Frequencies of CYP1A2 haplotypes (in order: rs2472299>rs2470890>rs11072508) in patients with prostate cancer and healthy controls.